These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 18355728)

  • 21. Apoptosis-inducing activity of the actin-depolymerizing agent aplyronine A and its side-chain derivatives.
    Ohno O; Morita M; Kitamura K; Teruya T; Yoneda K; Kita M; Kigoshi H; Suenaga K
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1467-71. PubMed ID: 23357626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design of protein-protein interaction inhibitors based on protein epitope mimetics.
    Robinson JA
    Chembiochem; 2009 Apr; 10(6):971-3. PubMed ID: 19266524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis, and biological evaluation of simplified side chain hybrids of the potent actin binding polyketides rhizopodin and bistramide.
    Herkommer D; Dreisigacker S; Sergeev G; Sasse F; Gohlke H; Menche D
    ChemMedChem; 2015 Mar; 10(3):470-89. PubMed ID: 25641798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neurite retraction and regrowth regulated by membrane retrieval, membrane supply, and actin dynamics.
    Prager-Khoutorsky M; Spira ME
    Brain Res; 2009 Jan; 1251():65-79. PubMed ID: 19022228
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of the F-actin-binding drugs, misakinolide A and swinholide A.
    Bubb MR; Spector I
    Methods Enzymol; 1998; 298():26-32. PubMed ID: 9751868
    [No Abstract]   [Full Text] [Related]  

  • 26. Synthetic non-peptide mimetics of alpha-helices.
    Davis JM; Tsou LK; Hamilton AD
    Chem Soc Rev; 2007 Feb; 36(2):326-34. PubMed ID: 17264933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New diketone based vanadium complexes as insulin mimetics.
    Sheela A; Roopan SM; Vijayaraghavan R
    Eur J Med Chem; 2008 Oct; 43(10):2206-10. PubMed ID: 18336956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peptides as protein binding site mimetics.
    Eichler J
    Curr Opin Chem Biol; 2008 Dec; 12(6):707-13. PubMed ID: 18935974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contractility-dependent actin dynamics in cardiomyocyte sarcomeres.
    Skwarek-Maruszewska A; Hotulainen P; Mattila PK; Lappalainen P
    J Cell Sci; 2009 Jun; 122(Pt 12):2119-26. PubMed ID: 19470580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluorescent aplyronine a: intracellular accumulation and disassembly of actin cytoskeleton in tumor cells.
    Kita M; Yoneda K; Hirayama Y; Yamagishi K; Saito Y; Sugiyama Y; Miwa Y; Ohno O; Morita M; Suenaga K; Kigoshi H
    Chembiochem; 2012 Aug; 13(12):1754-8, 1702. PubMed ID: 22807378
    [No Abstract]   [Full Text] [Related]  

  • 31. Interaction of diphtheria toxin (fragment A) with actin.
    Bektaş M; Varol B; Nurten R; Bermek E
    Cell Biochem Funct; 2009 Oct; 27(7):430-9. PubMed ID: 19711484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dynamic coupling between actin network flow and turnover revealed by flow mapping in the lamella of crawling fragments.
    Okeyo KO; Adachi T; Hojo M
    Biochem Biophys Res Commun; 2009 Dec; 390(3):797-802. PubMed ID: 19836353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Smac mimetics as new cancer therapeutics.
    Chen DJ; Huerta S
    Anticancer Drugs; 2009 Sep; 20(8):646-58. PubMed ID: 19550293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coarse-grained modeling and simulation of actin filament behavior based on Brownian dynamics method.
    Shimada Y; Adachi T; Inoue Y; Hojo M
    Mol Cell Biomech; 2009 Sep; 6(3):161-73. PubMed ID: 19670826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of photoaffinity derivatives of the antitumor macrolide aplyronine A, a PPI-inducer between actin and tubulin.
    Kita M; Yamagishi K; Tsuchiya K; Seguchi Y; Nakane H; Kigoshi H
    Bioorg Med Chem; 2017 Dec; 25(24):6322-6331. PubMed ID: 29042221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EF1A1-actin interactions alter mRNA stability to determine differential osteopontin expression in HepG2 and Hep3B cells.
    Zhang J; Guo H; Mi Z; Gao C; Bhattacharya S; Li J; Kuo PC
    Exp Cell Res; 2009 Jan; 315(2):304-12. PubMed ID: 19026636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Actin-targeting natural compounds as tools to study the role of actin cytoskeleton in signal transduction.
    Kustermans G; Piette J; Legrand-Poels S
    Biochem Pharmacol; 2008 Dec; 76(11):1310-22. PubMed ID: 18602087
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toxins affecting actin filaments and microtubules.
    Saito SY
    Prog Mol Subcell Biol; 2009; 46():187-219. PubMed ID: 19184589
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Properties of an ezrin mutant defective in F-actin binding.
    Saleh HS; Merkel U; Geissler KJ; Sperka T; Sechi A; Breithaupt C; Morrison H
    J Mol Biol; 2009 Jan; 385(4):1015-31. PubMed ID: 19084535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The structural determinants of macrolide-actin binding: in silico insights.
    Melville JL; Moal IH; Baker-Glenn C; Shaw PE; Pattenden G; Hirst JD
    Biophys J; 2007 Jun; 92(11):3862-7. PubMed ID: 17351011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.